Form 4: Ligand Pharmaceuticals CEO Todd C. Davis Reports Stock and Option Awards

CEO Todd C. Davis reports acquisition of restricted stock units and stock options in Ligand Pharmaceuticals.

Summary

• Todd C. Davis, CEO of Ligand Pharmaceuticals, reported the acquisition of 32,436 restricted stock units (RSUs) and 131,723 stock options on February 27, 2024.
• The RSUs vest in three equal annual installments starting February 15, 2025, and the stock options vest over 42 months after an initial 6-month period.
• Following these transactions, Davis directly owns 104,145 shares of Ligand Pharmaceuticals common stock and 131,723 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The vesting schedule suggests a long-term commitment from the CEO.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options incentivize long-term performance and retention.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded pharmaceutical companies such as Pfizer, Merck, and AbbVie.
• The vesting schedules and amounts granted to Todd C. Davis would need to be compared to peer companies to determine if they are in line with industry norms for CEOs of similar-sized pharmaceutical firms.

Stakeholder Impact

• The grant of stock options and RSUs could potentially increase shareholder value if the CEO's performance leads to company growth.
• Employees may be indirectly impacted by the CEO's incentives to improve company performance.

Key Dates